Latest News-Telix Pharmaceuticals Corporate Limited Mediaroom_Page

Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer

June 21, 2023, at The Yale Club, New York City Featured speakers and Key Opinion Leaders include: ...

2023-06-15 19:00 2875

Telix Opens European Radiopharmaceutical Production Facility

* Telix has unveiled its new, state-of-art radiopharmaceutical facility in Brussels South as part...

2023-06-08 20:00 3960

Telix to Present at Jefferies Healthcare Conference

MELBOURNE, Australia, June 6, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, ...

2023-06-06 08:40 3138

Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology

June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, dev...

2023-05-25 19:00 2792

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

MELBOURNE, Australia, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, t...

2023-05-08 05:00 6539

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

MELBOURNE, Australia and KYOTO, Japan, May 8, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (A...

2023-05-08 05:00 3841

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

MELBOURNE, Australia, May 2, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, t...

2023-05-02 05:00 3342

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

MELBOURNE, Australia, May 1, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, t...

2023-05-01 08:58 3878

Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

MELBOURNE, Australia, April 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-27 06:50 3657

Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-17 18:15 3332

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

MELBOURNE, Australia, April 17, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-17 06:38 2953

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

MELBOURNE, Australia, April 11, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-04-11 05:00 3239

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

INDIANAPOLIS, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Co...

2023-03-16 20:28 2591

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

MELBOURNE, Australia, March 16, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-03-16 08:28 3289

Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU

MELBOURNE, Australia, March 14, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix...

2023-03-14 05:11 2914

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

MELBOURNE, Australia, March 9, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2023-03-09 04:51 3493

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

MELBOURNE, Australia, Feb. 27, 2023 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix,...

2023-02-27 14:37 2953

Latest News

Telix Briefing: Innovation in Urology to Feature Key Opinion Leaders in Prostate and Kidney Cancer

Telix Opens European Radiopharmaceutical Production Facility

Telix to Present at Jefferies Healthcare Conference

Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study, including Japanese Sites

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

Telix Reports Q1 2023 Financial Results: Delivers First $100M Revenue Quarter

Olaratumab Antibody Licensed from Lilly Demonstrates Proof of Concept as a Theranostic Radiopharmaceutical

Chinese NMPA Approves Study of Telix Brain Cancer Therapy Candidate

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

FDA Approves Expanded Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Directed Radioligand Therapy

Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented in "Game Changing" Session at EAU

Telix to Showcase Additional ZIRCON Phase III Data in Kidney Cancer Imaging and Theranostic Pipeline Developments at EAU

Telix 2022 Full Year Results: Revenue up 20x in first year of commercial sales, underpins transition to cash flow positive

Detailed Results from Telix's ZIRCON Phase III Kidney Cancer Imaging Study Presented at ASCO GU

Telix Collaboration on Next Generation Urologic-Oncology Theranostic Published in Journal of Nuclear Medicine

Telix Reports Fourth Quarter 2022 Financial Results